Psych MEQs / SAQs · Psychopharmacology — benzodiazepine prescribing and tapering
Benzodiazepine initiation, conversion and taper (MEQ)
FRANZCP-style MEQ on benzodiazepine prescribing craft: opioid synergy, diazepam substitution, taper scaffold, deprescribing and escalation.
On this page & tools
Target exams
Model answers
(i) Harms and interaction risks (5 marks)
Answer
Counsel on physiological dependence, tolerance, interdose rebound with high-potency short-acting alprazolam, cognitive slowing, falls risk, and protracted withdrawal symptoms after dose cuts.[1][3][10] Emphasise opioid + benzodiazepine synergy: large data link concurrent use with overdose death; avoid casual stacking; review opioid indication and minimise combined CNS depression; naloxone does not reverse benzodiazepine effects.[5][2] Alcohol synergy, driving/occupation risk, and need for a single prescriber/pharmacy reconciliation complete the safety brief.[2][8]
(ii) Structured outpatient taper (7 marks)
Answer
Confirm actual daily alprazolam intake (prescribed vs taken). Convert to approximate diazepam equivalents (teaching anchor: alprazolam ~0.5 mg ≈ diazepam 10 mg — use local tables), stabilise on a long-acting vehicle if interdose symptoms dominate, then reduce about 10–25% of the daily dose every 1–2 weeks, slower near the end, with permission to pause for severe withdrawal.[1][2][3][8] Monitor withdrawal severity, mood/suicidality, alcohol/opioid escalation, falls, and driving. Structured strategies outperform abrupt advice; psychosocial support and education improve success.[4][9][6][7] If seizure or severe crisis: reinstate cover then slower taper — do not leave off all GABA-A PAM activity.[1][8]
(iii) Non-GABAergic plan (4 marks)
Answer
For underlying anxiety: SSRI/SNRI with CBT (or related evidence-based therapy). For insomnia: CBT-I, sleep hygiene, stimulus control; short-term non-GABAergic adjuncts only if needed after specialist judgement. Avoid replacing one automatic GABAergic renewal with another (e.g. chronic Z-drug) without indication review.[10][7][8]
(iv) Escalation red flags (4 marks)
Answer
Any of: history of withdrawal seizures or current seizure; very high-dose or chaotic multi-source use; unstable polysubstance use (alcohol/opioids) with medical risk; failed supervised outpatient taper with severe withdrawal; inability to engage safely in community (e.g. delirium, severe suicidality). Escalate to addiction/medical inpatient pathways with controlled GABA cover.[1][2][8]
References
- [1]Soyka M Treatment of Benzodiazepine Dependence N Engl J Med, 2017.PMID 28614686
- [2]Brett J, Murnion B Management of benzodiazepine misuse and dependence Aust Prescr, 2015.PMID 26648651
- [3]Ashton H The diagnosis and management of benzodiazepine dependence Curr Opin Psychiatry, 2005.PMID 16639148
- [4]Voshaar RC, Couvée JE, van Balkom AJ, et al. Strategies for discontinuing long-term benzodiazepine use: meta-analysis Br J Psychiatry, 2006.PMID 16946355
- [5]Sun EC, Dixit A, Humphreys K, et al. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis BMJ, 2017.PMID 28292769
- [6]Tannenbaum C, Martin P, Tamblyn R, et al. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial JAMA Intern Med, 2014.PMID 24733354
- [7]Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline Can Fam Physician, 2018.PMID 29760253
- [8]Brunner E, Chen CA, Klein T, et al. Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits J Gen Intern Med, 2025.PMID 40526204
- [9]Darker CD, Sweeney BP, Barry JM, et al. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence Cochrane Database Syst Rev, 2015.PMID 26106751
- [10]Guina J, Merrill B Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives J Clin Med, 2018.PMID 29385731